The European Medicines Agency has published new data on antimicrobial sales and use in animals across the European Union. The release updates a standing dataset that anchors antibiotic-stewardship policy across member states.

The release consolidates national sales reports covering veterinary antimicrobials, broken down by drug class and by country. Practitioners have tracked this series since the European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) project launched in 2011, when the EU set its first cross-border benchmarks for veterinary antibiotic consumption.

What does the release cover?

The release aggregates sales of veterinary antibiotics across participating EU member states. Reports express sales in milligrams per population correction unit (mg/PCU), a metric that adjusts total volumes for the size of each country's livestock population. Class-level breakdowns separate penicillins, tetracyclines, fluoroquinolones, polymyxins including colistin, and third- and fourth-generation cephalosporins. That level of granularity shapes downstream policy.

Each drug class carries its own regulatory trajectory under EU antimicrobial resistance (AMR) strategy. Shifts in category-specific sales determine which molecules face prescribing restrictions in the next cycle.

What changes at the clinic?

For companion-animal practitioners, the dataset rarely shifts day-to-day prescribing. The data feed upstream decisions that filter down through national regulators: product withdrawals, label restrictions, and veterinarian-side dispensing rules. Several member states tightened access to certain fluoroquinolones and third-generation cephalosporins for companion-animal use in recent years.

For food-animal veterinarians, the implications land more directly. The European Food Safety Authority (EFSA) and EMA cross-reference ESVAC sales data with resistance trends measured in zoonic pathogens. The combined picture drives restrictions on prophylactic group treatments, and EU-wide bans on routine feed-grade antibiotic use in food-producing animals took effect January 28, 2022.

Ban took effect. Sales followed.

Section takeaway: data revisions in this dataset set the regulatory clock for prescribing decisions in the EU for the next twelve months.

What changes for public health?

The One Health framing under EU AMR policy ties veterinary reporting directly to human-health outcomes. The European Centre for Disease Prevention and Control measures resistance trends in Salmonella, Campylobacter, and Escherichia coli from human clinical isolates. Veterinary sales reductions in critical classes track alongside resistance declines in the corresponding zoonotic strains.

Trend lines tell the story.

Section takeaway: antibiotic sales in food animals remain a measurable upstream driver of resistance patterns in human clinical isolates.

What should practitioners watch?

Member states showing persistently elevated per-capita veterinary antimicrobial sales face heightened regulatory scrutiny. The next revision cycle typically tightens prescribing restrictions first in those higher-use jurisdictions.

Watch the class-level trends.

Bottom line for the practitioner: this release is the annual baseline. Clinics that track the class-level shifts stay ahead of the next prescribing restriction.

The EMA's annual update sets the regulatory baseline for veterinary antimicrobial prescribing across the EU through the next reporting cycle.